Recursion Pharmaceuticals, Inc. (RXRX) 10-Year Financial Performance & Capital Metrics

RXRX •

HealthcareBiotechnologyDrug Discovery and Antibody Platforms

AboutRecursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.Show more

Revenue $75M +26.9%
EBITDA -$564M -27.6%
Net Income -$645M -39.1%
EPS (Diluted) -1.44 +14.8%
Gross Margin 4.99% -78.4%
EBITDA Margin -755.79% -0.5%
Operating Margin -867.87% -6.6%
Net Margin -863.35% -9.6%
ROE -59.54% +3.8%
ROIC -95.83% +10.4%
Debt/Equity 0.07 -34.2%
Interest Coverage -358.08 -17.5%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Strong 5Y sales CAGR of 85.4%
✓Trading at only 1.5x book value

✗Weaknesses

✗Negative free cash flow
✗Weak momentum: RS Rating 20 (bottom 20%)
✗Shares diluted 63.2% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y85.36%

3Y23.46%

TTM27.48%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-39.11%

EPS CAGR

10Y-

5Y-

3Y-

TTM10.84%

ROCE

10Y Avg-51.48%

5Y Avg-49.74%

3Y Avg-54.32%

Latest-50.1%

Peer Comparison

Drug Discovery and Antibody Platforms

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
REGNRegeneron Pharmaceuticals, Inc.	107.56B	781.67	18.84	0.99%	31.41%	14.41%	3.79%	0.09
CTMXCytomX Therapeutics, Inc.	430.14M	5.37	14.13	36.45%	24.66%	26.09%
PRTCPureTech Health plc	405.3M	16.77	8.39	44.98%	-495.91%	-8.53%		0.05
DNAGinkgo Bioworks Holdings, Inc.	327.53M	6.75	-1.20	-25.06%	-183.81%	-61.5%		0.82
BCYCBicycle Therapeutics plc	111.38M	5.73	-1.98	30.76%	-8.85%	-40.53%		0.01
CCCCC4 Therapeutics, Inc.	261.67M	2.70	-2.13	-100%		-40.92%		0.23
MOLNMolecular Partners AG	187.84M	5.02	-2.43	-29.38%	-10.87%	-63.06%		0.02
RXRXRecursion Pharmaceuticals, Inc.	1.94B	3.67	-2.55	26.92%	-8.65%	-57.01%		0.07

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Sales/Revenue+	1.71M	3.41M	10M	39.68M	43.88M	58.84M	74.68M
Revenue Growth %	-	99.47%	193%	296.81%	10.57%	34.1%	26.92%
Cost of Goods Sold+	45.81M	0	0	48.27M	42.59M	45.24M	70.95M
COGS % of Revenue	2677.32%	-	-	121.66%	97.06%	76.88%	95.01%
Gross Profit+	-44.1M	3.41M	10M	-8.59M	1.29M	13.6M	3.73M
Gross Margin %	-2577.32%	100%	100%	-21.66%	2.94%	23.12%	4.99%
Gross Profit Growth %	-	107.74%	193%	-185.94%	115%	955.16%	-72.59%
Operating Expenses+	64.15M	88.03M	192.78M	237.13M	351.35M	492.61M	651.86M
OpEx % of Revenue	3749.39%	2579.2%	1927.75%	597.6%	800.78%	837.21%	872.86%
Selling, General & Admin	18.95M	25.26M	57.68M	81.6M	110.82M	178.18M	176.59M
SG&A % of Revenue	1107.6%	740.05%	576.82%	205.64%	252.58%	302.83%	236.46%
Research & Development	45.81M	63.32M	135.27M	155.7M	241.23M	314.42M	475.27M
R&D % of Revenue	2677.32%	1855.23%	1352.71%	392.37%	549.79%	534.38%	636.4%
Other Operating Expenses	-608K	-549K	-178K	-162K	-699K	0	0
Operating Income+	-62.44M	-84.61M	-182.78M	-245.73M	-350.06M	-479M	-648.13M
Operating Margin %	-3649.39%	-2479.2%	-1827.75%	-619.26%	-797.84%	-814.09%	-867.87%
Operating Income Growth %	-	-35.51%	-116.01%	-34.44%	-42.46%	-36.83%	-35.31%
EBITDA+	-58.9M	-80.67M	-174.37M	-233.97M	-325.66M	-442.51M	-564.43M
EBITDA Margin %	-3442.31%	-2363.67%	-1743.7%	-589.63%	-742.22%	-752.07%	-755.79%
EBITDA Growth %	-	-36.97%	-116.15%	-34.18%	-39.19%	-35.88%	-27.55%
D&A (Non-Cash Add-back)	3.54M	3.94M	8.4M	11.76M	24.4M	36.49M	83.7M
EBIT	-61.88M	-85.65M	-183.53M	-239.42M	-332.03M	-463.22M	-644.89M
Net Interest Income+	1.11M	-1.02M	-2.88M	6.2M	19.02M	14.19M	20.98M
Interest Income	1.74M	336K	73K	6.25M	19.12M	15.76M	22.79M
Interest Expense	635K	1.36M	2.95M	55K	97K	1.57M	1.81M
Other Income/Expense	562K	-2.39M	-3.7M	6.25M	17.93M	14.22M	3.24M
Pretax Income+	-61.88M	-87.01M	-186.48M	-239.48M	-332.13M	-464.79M	-644.89M
Pretax Margin %	-3616.54%	-2549.25%	-1864.79%	-603.5%	-756.97%	-789.93%	-863.53%
Income Tax+	0	0	0	0	-4.06M	-1.13M	-136K
Effective Tax Rate %	101.04%	100%	100%	100%	98.78%	99.76%	99.98%
Net Income+	-62.52M	-87.01M	-186.48M	-239.48M	-328.07M	-463.66M	-644.76M
Net Margin %	-3654.3%	-2549.25%	-1864.79%	-603.5%	-747.71%	-788.02%	-863.35%
Net Income Growth %	-	-39.15%	-114.33%	-28.42%	-36.99%	-41.33%	-39.06%
Net Income (Continuing)	-61.88M	-87.01M	-186.48M	-239.48M	-328.07M	-463.66M	-644.76M
Discontinued Operations	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0
EPS (Diluted)+	-0.37	-0.52	-1.05	-1.36	-1.58	-1.69	-1.44
EPS Growth %	-	-40.62%	-100.08%	-29.52%	-16.18%	-6.96%	14.79%
EPS (Basic)	-0.37	-0.52	-1.05	-1.36	-1.58	-1.69	-1.44
Diluted Shares Outstanding	165.79M	165.79M	170.27M	175.54M	207.85M	274.21M	447.45M
Basic Shares Outstanding	165.79M	165.79M	170.27M	175.54M	207.85M	274.21M	447.45M
Dividend Payout Ratio	-	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Current Assets+	76.4M	266.44M	534.72M	569.81M	438.14M	714.27M	812.85M
Cash & Short-Term Investments	69.88M	262.13M	516.56M	549.91M	391.56M	594.35M	743.29M
Cash Only	69.88M	262.13M	285.12M	549.91M	391.56M	594.35M	743.29M
Short-Term Investments	0	0	231.45M	0	0	0	0
Accounts Receivable	151K	156K	9.09M	2.75M	3.09M	49.17M	24.65M
Days Sales Outstanding	32.21	16.68	331.79	25.32	25.74	304.99	120.47
Inventory	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-
Other Current Assets	6.36M	4.16M	9.07M	17.15M	43.48M	70.75M	44.9M
Total Non-Current Assets+	25.03M	32.15M	75.63M	131.47M	215.56M	734.33M	661.28M
Property, Plant & Equipment	24.37M	25.97M	64.72M	121.45M	120.17M	233.21M	169.48M
Fixed Asset Turnover	0.07x	0.13x	0.15x	0.33x	0.37x	0.25x	0.44x
Goodwill	0	801K	801K	801K	52.06M	148.87M	162.16M
Intangible Assets	0	1.69M	1.39M	1.31M	36.44M	335.86M	309.9M
Long-Term Investments	0	0	0	0	0	5.63M	0
Other Non-Current Assets	663K	3.69M	8.72M	7.92M	6.89M	8.82M	18.79M
Total Assets+	101.43M	298.58M	610.35M	701.29M	653.7M	1.45B	1.47B
Asset Turnover	0.02x	0.01x	0.02x	0.06x	0.07x	0.04x	0.05x
Asset Growth %	-	194.37%	104.41%	14.9%	-6.79%	121.6%	1.76%
Total Current Liabilities+	6.68M	23.1M	46.66M	100.27M	93.17M	187.47M	147.71M
Accounts Payable	1.26M	1.07M	2.82M	4.59M	3.95M	21.61M	18.12M
Days Payables Outstanding	10.05	-	-	34.67	33.88	174.38	93.2
Short-Term Debt	77K	1.07M	90K	97K	41K	22.22M	21.75M
Deferred Revenue (Current)	0	10M	10M	56.73M	36.43M	61.77M	37.6M
Other Current Liabilities	1.7M	3.08M	11.74M	20.43M	23.75M	81.87M	70.23M
Current Ratio	11.43x	11.53x	11.46x	5.68x	4.70x	3.81x	5.50x
Quick Ratio	11.43x	11.53x	11.46x	5.68x	4.70x	3.81x	5.50x
Cash Conversion Cycle	-	-	-	-	-	-	-
Total Non-Current Liabilities+	219.01M	481.77M	20.75M	115.22M	97.09M	226.34M	195.56M
Long-Term Debt	12.42M	11.41M	633K	536K	1.1M	19.02M	56.21M
Capital Lease Obligations	3.21M	2.71M	9.34M	44.42M	43.41M	67.25M	0
Deferred Tax Liabilities	0	0	0	0	1.34M	16.57M	23.25M
Other Non-Current Liabilities	203.39M	450.99M	4.11M	0	0	4.73M	116.09M
Total Liabilities	225.7M	504.87M	67.41M	215.48M	190.26M	413.82M	343.26M
Total Debt+	16.17M	15.66M	11.48M	51.01M	50.67M	108.49M	77.97M
Net Debt	-53.71M	-246.46M	-273.64M	-498.91M	-340.89M	-485.86M	-665.33M
Debt / Equity	-	-	0.02x	0.10x	0.11x	0.10x	0.07x
Debt / EBITDA	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-
Interest Coverage	-98.33x	-62.22x	-61.92x	-4467.76x	-3608.87x	-304.71x	-358.08x
Total Equity+	-124.27M	-206.29M	542.94M	485.81M	463.44M	1.03B	1.13B
Equity Growth %	-	-66.01%	363.19%	-10.52%	-4.6%	123.28%	9.29%
Book Value per Share	-0.75	-1.24	3.19	2.77	2.23	3.77	2.53
Total Shareholders' Equity	-124.27M	-206.29M	542.94M	485.81M	463.44M	1.03B	1.13B
Common Stock	0	0	2K	2K	2K	4K	5K
Retained Earnings	-126.59M	-213.6M	-400.08M	-639.56M	-967.62M	-1.43B	-2.08B
Treasury Stock	0	0	0	0	0	0	0
Accumulated OCI	0	0	-126K	0	0	-7.64M	36.72M
Minority Interest	0	0	0	0	0	0	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Cash from Operations+	-57.04M	-45.4M	-158.61M	-83.52M	-287.78M	-359.17M	-371.81M
Operating CF Margin %	-3333.84%	-1330.18%	-1586.14%	-210.49%	-655.89%	-610.44%	-497.86%
Operating CF Growth %	-	20.41%	-249.38%	47.34%	-244.55%	-24.81%	-3.52%
Net Income	-61.88M	-87.01M	-186.48M	-239.48M	-328.07M	-463.66M	-644.76M
Depreciation & Amortization	2.49M	3.94M	8.4M	11.76M	24.4M	36.49M	83.7M
Stock-Based Compensation	1.39M	4.29M	14.84M	27.91M	53.5M	81.69M	111.22M
Deferred Taxes	0	0	827K	0	0	0	0
Other Non-Cash Items	555K	2.54M	4.1M	11.37M	12.64M	24.31M	64.34M
Working Capital Changes	408K	30.83M	-306K	104.92M	-50.26M	-38M	13.69M
Change in Receivables	605K	-1.12M	114K	-2K	0	-6.07M	32.94M
Change in Inventory	0	0	7.83M	0	0	0	0
Change in Payables	-340K	-185K	1.75M	1.77M	-987K	6.43M	-2.62M
Cash from Investing+	-3.91M	-8.74M	-271.74M	193.25M	-10.23M	260.06M	-16.87M
Capital Expenditures	-3.91M	-5.83M	-39.8M	-37.06M	-11.96M	-13.7M	-6.47M
CapEx % of Revenue	228.52%	170.85%	397.98%	93.39%	27.25%	23.28%	8.66%
Acquisitions	0	-2.6M	231.95M	0	1.84M	277.1M	0
Investments	-	-	-	-	-	-	-
Other Investing	0	-309K	-231.95M	-300K	-597K	-3.35M	-6.6M
Cash from Financing+	120.41M	246.13M	458.54M	154.34M	140.13M	304.12M	521.53M
Debt Issued (Net)	705K	6.32M	-12.8M	-90K	-766K	-4.44M	-8.43M
Equity Issued (Net)	1000K	1000K	1000K	1000K	1000K	1000K	1000K
Dividends Paid	0	0	0	0	0	0	0
Share Repurchases	0	0	0	0	0	0	0
Other Financing	-210K	681K	8.44M	10.72M	12.81M	8.14M	-3M
Net Change in Cash	59.46M	192M	28.18M	263.76M	-157.69M	201.6M	150.9M
Free Cash Flow+	-60.95M	-52.13M	-198.41M	-120.88M	-300.33M	-372.87M	-378.28M
FCF Margin %	-3562.36%	-1527.51%	-1984.12%	-304.64%	-684.5%	-633.71%	-506.52%
FCF Growth %	-	14.47%	-280.58%	39.07%	-148.45%	-24.15%	-1.45%
FCF per Share	-0.37	-0.31	-1.17	-0.69	-1.44	-1.36	-0.85
FCF Conversion (FCF/Net Income)	0.91x	0.52x	0.85x	0.35x	0.88x	0.77x	0.58x
Interest Paid	485K	989K	0	55K	0	0	0
Taxes Paid	0	0	0	0	0	0	0

Key Ratios

Metric	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-	-	-110.79%	-46.56%	-69.12%	-61.9%	-59.54%
Return on Invested Capital (ROIC)	-	-	-	-143.87%	-479.79%	-107.01%	-95.83%
Gross Margin	-2577.32%	100%	100%	-21.66%	2.94%	23.12%	4.99%
Net Margin	-3654.3%	-2549.25%	-1864.79%	-603.5%	-747.71%	-788.02%	-863.35%
Debt / Equity	-	-	0.02x	0.10x	0.11x	0.10x	0.07x
Interest Coverage	-98.33x	-62.22x	-61.92x	-4467.76x	-3608.87x	-304.71x	-358.08x
FCF Conversion	0.91x	0.52x	0.85x	0.35x	0.88x	0.77x	0.58x
Revenue Growth	-	99.47%	193%	296.81%	10.57%	34.1%	26.92%

US Stock Screener

...

Recursion Pharmaceuticals, Inc. (RXRX) 10-Year Financial Performance & Capital Metrics

RXRX •

HealthcareBiotechnologyDrug Discovery and Antibody Platforms

Revenue $75M +26.9%
EBITDA -$564M -27.6%
Net Income -$645M -39.1%
EPS (Diluted) -1.44 +14.8%
Gross Margin 4.99% -78.4%
EBITDA Margin -755.79% -0.5%
Operating Margin -867.87% -6.6%
Net Margin -863.35% -9.6%
ROE -59.54% +3.8%
ROIC -95.83% +10.4%
Debt/Equity 0.07 -34.2%
Interest Coverage -358.08 -17.5%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Strong 5Y sales CAGR of 85.4%
✓Trading at only 1.5x book value

✗Weaknesses

✗Negative free cash flow
✗Weak momentum: RS Rating 20 (bottom 20%)
✗Shares diluted 63.2% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y85.36%

3Y23.46%

TTM27.48%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-39.11%

EPS CAGR

10Y-

5Y-

3Y-

TTM10.84%

ROCE

10Y Avg-51.48%

5Y Avg-49.74%

3Y Avg-54.32%

Latest-50.1%

Peer Comparison

Drug Discovery and Antibody Platforms

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
REGNRegeneron Pharmaceuticals, Inc.	107.56B	781.67	18.84	0.99%	31.41%	14.41%	3.79%	0.09
CTMXCytomX Therapeutics, Inc.	430.14M	5.37	14.13	36.45%	24.66%	26.09%
PRTCPureTech Health plc	405.3M	16.77	8.39	44.98%	-495.91%	-8.53%		0.05
DNAGinkgo Bioworks Holdings, Inc.	327.53M	6.75	-1.20	-25.06%	-183.81%	-61.5%		0.82
BCYCBicycle Therapeutics plc	111.38M	5.73	-1.98	30.76%	-8.85%	-40.53%		0.01
CCCCC4 Therapeutics, Inc.	261.67M	2.70	-2.13	-100%		-40.92%		0.23
MOLNMolecular Partners AG	187.84M	5.02	-2.43	-29.38%	-10.87%	-63.06%		0.02
RXRXRecursion Pharmaceuticals, Inc.	1.94B	3.67	-2.55	26.92%	-8.65%	-57.01%		0.07

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Sales/Revenue+	1.71M	3.41M	10M	39.68M	43.88M	58.84M	74.68M
Revenue Growth %	-	99.47%	193%	296.81%	10.57%	34.1%	26.92%
Cost of Goods Sold+	45.81M	0	0	48.27M	42.59M	45.24M	70.95M
COGS % of Revenue	2677.32%	-	-	121.66%	97.06%	76.88%	95.01%
Gross Profit+	-44.1M	3.41M	10M	-8.59M	1.29M	13.6M	3.73M
Gross Margin %	-2577.32%	100%	100%	-21.66%	2.94%	23.12%	4.99%
Gross Profit Growth %	-	107.74%	193%	-185.94%	115%	955.16%	-72.59%
Operating Expenses+	64.15M	88.03M	192.78M	237.13M	351.35M	492.61M	651.86M
OpEx % of Revenue	3749.39%	2579.2%	1927.75%	597.6%	800.78%	837.21%	872.86%
Selling, General & Admin	18.95M	25.26M	57.68M	81.6M	110.82M	178.18M	176.59M
SG&A % of Revenue	1107.6%	740.05%	576.82%	205.64%	252.58%	302.83%	236.46%
Research & Development	45.81M	63.32M	135.27M	155.7M	241.23M	314.42M	475.27M
R&D % of Revenue	2677.32%	1855.23%	1352.71%	392.37%	549.79%	534.38%	636.4%
Other Operating Expenses	-608K	-549K	-178K	-162K	-699K	0	0
Operating Income+	-62.44M	-84.61M	-182.78M	-245.73M	-350.06M	-479M	-648.13M
Operating Margin %	-3649.39%	-2479.2%	-1827.75%	-619.26%	-797.84%	-814.09%	-867.87%
Operating Income Growth %	-	-35.51%	-116.01%	-34.44%	-42.46%	-36.83%	-35.31%
EBITDA+	-58.9M	-80.67M	-174.37M	-233.97M	-325.66M	-442.51M	-564.43M
EBITDA Margin %	-3442.31%	-2363.67%	-1743.7%	-589.63%	-742.22%	-752.07%	-755.79%
EBITDA Growth %	-	-36.97%	-116.15%	-34.18%	-39.19%	-35.88%	-27.55%
D&A (Non-Cash Add-back)	3.54M	3.94M	8.4M	11.76M	24.4M	36.49M	83.7M
EBIT	-61.88M	-85.65M	-183.53M	-239.42M	-332.03M	-463.22M	-644.89M
Net Interest Income+	1.11M	-1.02M	-2.88M	6.2M	19.02M	14.19M	20.98M
Interest Income	1.74M	336K	73K	6.25M	19.12M	15.76M	22.79M
Interest Expense	635K	1.36M	2.95M	55K	97K	1.57M	1.81M
Other Income/Expense	562K	-2.39M	-3.7M	6.25M	17.93M	14.22M	3.24M
Pretax Income+	-61.88M	-87.01M	-186.48M	-239.48M	-332.13M	-464.79M	-644.89M
Pretax Margin %	-3616.54%	-2549.25%	-1864.79%	-603.5%	-756.97%	-789.93%	-863.53%
Income Tax+	0	0	0	0	-4.06M	-1.13M	-136K
Effective Tax Rate %	101.04%	100%	100%	100%	98.78%	99.76%	99.98%
Net Income+	-62.52M	-87.01M	-186.48M	-239.48M	-328.07M	-463.66M	-644.76M
Net Margin %	-3654.3%	-2549.25%	-1864.79%	-603.5%	-747.71%	-788.02%	-863.35%
Net Income Growth %	-	-39.15%	-114.33%	-28.42%	-36.99%	-41.33%	-39.06%
Net Income (Continuing)	-61.88M	-87.01M	-186.48M	-239.48M	-328.07M	-463.66M	-644.76M
Discontinued Operations	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0
EPS (Diluted)+	-0.37	-0.52	-1.05	-1.36	-1.58	-1.69	-1.44
EPS Growth %	-	-40.62%	-100.08%	-29.52%	-16.18%	-6.96%	14.79%
EPS (Basic)	-0.37	-0.52	-1.05	-1.36	-1.58	-1.69	-1.44
Diluted Shares Outstanding	165.79M	165.79M	170.27M	175.54M	207.85M	274.21M	447.45M
Basic Shares Outstanding	165.79M	165.79M	170.27M	175.54M	207.85M	274.21M	447.45M
Dividend Payout Ratio	-	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Current Assets+	76.4M	266.44M	534.72M	569.81M	438.14M	714.27M	812.85M
Cash & Short-Term Investments	69.88M	262.13M	516.56M	549.91M	391.56M	594.35M	743.29M
Cash Only	69.88M	262.13M	285.12M	549.91M	391.56M	594.35M	743.29M
Short-Term Investments	0	0	231.45M	0	0	0	0
Accounts Receivable	151K	156K	9.09M	2.75M	3.09M	49.17M	24.65M
Days Sales Outstanding	32.21	16.68	331.79	25.32	25.74	304.99	120.47
Inventory	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-
Other Current Assets	6.36M	4.16M	9.07M	17.15M	43.48M	70.75M	44.9M
Total Non-Current Assets+	25.03M	32.15M	75.63M	131.47M	215.56M	734.33M	661.28M
Property, Plant & Equipment	24.37M	25.97M	64.72M	121.45M	120.17M	233.21M	169.48M
Fixed Asset Turnover	0.07x	0.13x	0.15x	0.33x	0.37x	0.25x	0.44x
Goodwill	0	801K	801K	801K	52.06M	148.87M	162.16M
Intangible Assets	0	1.69M	1.39M	1.31M	36.44M	335.86M	309.9M
Long-Term Investments	0	0	0	0	0	5.63M	0
Other Non-Current Assets	663K	3.69M	8.72M	7.92M	6.89M	8.82M	18.79M
Total Assets+	101.43M	298.58M	610.35M	701.29M	653.7M	1.45B	1.47B
Asset Turnover	0.02x	0.01x	0.02x	0.06x	0.07x	0.04x	0.05x
Asset Growth %	-	194.37%	104.41%	14.9%	-6.79%	121.6%	1.76%
Total Current Liabilities+	6.68M	23.1M	46.66M	100.27M	93.17M	187.47M	147.71M
Accounts Payable	1.26M	1.07M	2.82M	4.59M	3.95M	21.61M	18.12M
Days Payables Outstanding	10.05	-	-	34.67	33.88	174.38	93.2
Short-Term Debt	77K	1.07M	90K	97K	41K	22.22M	21.75M
Deferred Revenue (Current)	0	10M	10M	56.73M	36.43M	61.77M	37.6M
Other Current Liabilities	1.7M	3.08M	11.74M	20.43M	23.75M	81.87M	70.23M
Current Ratio	11.43x	11.53x	11.46x	5.68x	4.70x	3.81x	5.50x
Quick Ratio	11.43x	11.53x	11.46x	5.68x	4.70x	3.81x	5.50x
Cash Conversion Cycle	-	-	-	-	-	-	-
Total Non-Current Liabilities+	219.01M	481.77M	20.75M	115.22M	97.09M	226.34M	195.56M
Long-Term Debt	12.42M	11.41M	633K	536K	1.1M	19.02M	56.21M
Capital Lease Obligations	3.21M	2.71M	9.34M	44.42M	43.41M	67.25M	0
Deferred Tax Liabilities	0	0	0	0	1.34M	16.57M	23.25M
Other Non-Current Liabilities	203.39M	450.99M	4.11M	0	0	4.73M	116.09M
Total Liabilities	225.7M	504.87M	67.41M	215.48M	190.26M	413.82M	343.26M
Total Debt+	16.17M	15.66M	11.48M	51.01M	50.67M	108.49M	77.97M
Net Debt	-53.71M	-246.46M	-273.64M	-498.91M	-340.89M	-485.86M	-665.33M
Debt / Equity	-	-	0.02x	0.10x	0.11x	0.10x	0.07x
Debt / EBITDA	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-
Interest Coverage	-98.33x	-62.22x	-61.92x	-4467.76x	-3608.87x	-304.71x	-358.08x
Total Equity+	-124.27M	-206.29M	542.94M	485.81M	463.44M	1.03B	1.13B
Equity Growth %	-	-66.01%	363.19%	-10.52%	-4.6%	123.28%	9.29%
Book Value per Share	-0.75	-1.24	3.19	2.77	2.23	3.77	2.53
Total Shareholders' Equity	-124.27M	-206.29M	542.94M	485.81M	463.44M	1.03B	1.13B
Common Stock	0	0	2K	2K	2K	4K	5K
Retained Earnings	-126.59M	-213.6M	-400.08M	-639.56M	-967.62M	-1.43B	-2.08B
Treasury Stock	0	0	0	0	0	0	0
Accumulated OCI	0	0	-126K	0	0	-7.64M	36.72M
Minority Interest	0	0	0	0	0	0	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Cash from Operations+	-57.04M	-45.4M	-158.61M	-83.52M	-287.78M	-359.17M	-371.81M
Operating CF Margin %	-3333.84%	-1330.18%	-1586.14%	-210.49%	-655.89%	-610.44%	-497.86%
Operating CF Growth %	-	20.41%	-249.38%	47.34%	-244.55%	-24.81%	-3.52%
Net Income	-61.88M	-87.01M	-186.48M	-239.48M	-328.07M	-463.66M	-644.76M
Depreciation & Amortization	2.49M	3.94M	8.4M	11.76M	24.4M	36.49M	83.7M
Stock-Based Compensation	1.39M	4.29M	14.84M	27.91M	53.5M	81.69M	111.22M
Deferred Taxes	0	0	827K	0	0	0	0
Other Non-Cash Items	555K	2.54M	4.1M	11.37M	12.64M	24.31M	64.34M
Working Capital Changes	408K	30.83M	-306K	104.92M	-50.26M	-38M	13.69M
Change in Receivables	605K	-1.12M	114K	-2K	0	-6.07M	32.94M
Change in Inventory	0	0	7.83M	0	0	0	0
Change in Payables	-340K	-185K	1.75M	1.77M	-987K	6.43M	-2.62M
Cash from Investing+	-3.91M	-8.74M	-271.74M	193.25M	-10.23M	260.06M	-16.87M
Capital Expenditures	-3.91M	-5.83M	-39.8M	-37.06M	-11.96M	-13.7M	-6.47M
CapEx % of Revenue	228.52%	170.85%	397.98%	93.39%	27.25%	23.28%	8.66%
Acquisitions	0	-2.6M	231.95M	0	1.84M	277.1M	0
Investments	-	-	-	-	-	-	-
Other Investing	0	-309K	-231.95M	-300K	-597K	-3.35M	-6.6M
Cash from Financing+	120.41M	246.13M	458.54M	154.34M	140.13M	304.12M	521.53M
Debt Issued (Net)	705K	6.32M	-12.8M	-90K	-766K	-4.44M	-8.43M
Equity Issued (Net)	1000K	1000K	1000K	1000K	1000K	1000K	1000K
Dividends Paid	0	0	0	0	0	0	0
Share Repurchases	0	0	0	0	0	0	0
Other Financing	-210K	681K	8.44M	10.72M	12.81M	8.14M	-3M
Net Change in Cash	59.46M	192M	28.18M	263.76M	-157.69M	201.6M	150.9M
Free Cash Flow+	-60.95M	-52.13M	-198.41M	-120.88M	-300.33M	-372.87M	-378.28M
FCF Margin %	-3562.36%	-1527.51%	-1984.12%	-304.64%	-684.5%	-633.71%	-506.52%
FCF Growth %	-	14.47%	-280.58%	39.07%	-148.45%	-24.15%	-1.45%
FCF per Share	-0.37	-0.31	-1.17	-0.69	-1.44	-1.36	-0.85
FCF Conversion (FCF/Net Income)	0.91x	0.52x	0.85x	0.35x	0.88x	0.77x	0.58x
Interest Paid	485K	989K	0	55K	0	0	0
Taxes Paid	0	0	0	0	0	0	0

Key Ratios

Metric	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-	-	-110.79%	-46.56%	-69.12%	-61.9%	-59.54%
Return on Invested Capital (ROIC)	-	-	-	-143.87%	-479.79%	-107.01%	-95.83%
Gross Margin	-2577.32%	100%	100%	-21.66%	2.94%	23.12%	4.99%
Net Margin	-3654.3%	-2549.25%	-1864.79%	-603.5%	-747.71%	-788.02%	-863.35%
Debt / Equity	-	-	0.02x	0.10x	0.11x	0.10x	0.07x
Interest Coverage	-98.33x	-62.22x	-61.92x	-4467.76x	-3608.87x	-304.71x	-358.08x
FCF Conversion	0.91x	0.52x	0.85x	0.35x	0.88x	0.77x	0.58x
Revenue Growth	-	99.47%	193%	296.81%	10.57%	34.1%	26.92%

Recursion Pharmaceuticals, Inc. (RXRX) 10-Year Financial Performance & Capital Metrics

Key Insights

✓Strengths

✗Weaknesses

Price & Volume

Growth Metrics

Revenue CAGR

Profit (Net Income) CAGR

EPS CAGR

ROCE

Peer Comparison

Compare RXRX vs Peers

vs REGN

vs CNTA

Compare Top 5

Profit & Loss

Balance Sheet

Cash Flow

Key Ratios

Deep Dive Analysis

Valuation Overview

Total Return Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Recursion Pharmaceuticals, Inc. (RXRX) 10-Year Financial Performance & Capital Metrics

Key Insights

✓Strengths

✗Weaknesses

Price & Volume

Growth Metrics

Revenue CAGR

Profit (Net Income) CAGR

EPS CAGR

ROCE

Peer Comparison

Compare RXRX vs Peers

vs REGN

vs CNTA

Compare Top 5

Profit & Loss

Balance Sheet

Cash Flow

Key Ratios

Deep Dive Analysis

Valuation Overview

Total Return Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios